OMEROS
Omeros is a Seattle-based commercial-stage biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases and disorders of the central nervous system.
OMEROS
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
1994-01-01
Address:
Seattle, Washington, United States
Country:
United States
Website Url:
http://www.omeros.com
Total Employee:
51+
Status:
Active
Contact:
2066765005
Total Funding:
965.36 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Font Awesome Apache
Similar Organizations
Adamas Pharmaceuticals
Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
AZTherapies
AZTherapies is a clinical stage biotech company developing breakthrough treatments for neuroinflammation-related diseases.
Emmaus Medical
Emmaus Medical is a pharmaceutical company developing new treatments for rare diseases and conditions.
Euthymics Bioscience
Euthymics Bioscience, a neuroscience-focused biopharmaceutical company, develops medicines for central nervous system disorders.
NovaBay Pharmaceuticals
NovaBay Pharmaceuticals is a biopharmaceutical company developing products for the eye care market.
Oculis
Oculis is a clinical-stage, privately held, pharmaceutical development company focusing on ophthalmic drugs and novel drug delivery.
Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases.
Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2006-09-07 | Nura | Nura acquired by Omeros | N/A |
Investors List
CRG
CRG investment in Post-IPO Debt - Omeros
Oxford Finance LLC
Oxford Finance LLC investment in Post-IPO Debt - Omeros
East West Bank
East West Bank investment in Post-IPO Debt - Omeros
Oxford Finance LLC
Oxford Finance LLC investment in Post-IPO Debt - Omeros
East West Bank
East West Bank investment in Post-IPO Debt - Omeros
Oxford Finance LLC
Oxford Finance LLC investment in Post-IPO Debt - Omeros
MidCap Financial
MidCap Financial investment in Post-IPO Debt - Omeros
National Institute of Mental Health
National Institute of Mental Health investment in Grant - Omeros
National Institute on Drug Abuse (NIDA)
National Institute on Drug Abuse (NIDA) investment in Grant - Omeros
Life Sciences Discovery Fund
Life Sciences Discovery Fund investment in Grant - Omeros
Newest Events participated
Official Site Inspections
http://www.omeros.com Semrush global rank: 2.18 M Semrush visits lastest month: 9.05 K
- Host name: 104.20.42.239
- IP address: 104.20.42.239
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Omeros"
Omeros Leadership Team & Board of Directors
Omeros’ leadership team and board of directors contribute diverse expertise and proven leadership, helping us navigate the complex terrain of biopharmaceutical development. ... Dr …See details»
Management Team - Omeros
Prior to joining Omeros in this role, Dr. Meiklejohn was an expert CMC consultant for several biotechnology companies, including Omeros. His consulting work followed a distinguished …See details»
About Omeros – Clinical Studies & Company Milestones
Omeros enters funding agreements for our GPCR discovery program with Vulcan Inc. and Washington State Life Science Discovery Fund . Omeros establishes a charitable entity to fund nonprofit life sciences organizations in Washington …See details»
Omeros - Crunchbase Company Profile & Funding
Omeros is a Seattle-based commercial-stage biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for …See details»
Omeros Corporation - LinkedIn
Omeros Corporation | 10,617 followers on LinkedIn. Let science lead the way | Omeros is a Seattle-based biopharmaceutical company committed to discovering, developing, and commercializing small ...See details»
Omeros Company Profile | Management and Employees List
Omeros Profile and History. Omeros is a Seattle-based biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for …See details»
Omeros Corporation Company Profile | Seattle, WA | Competitors ...
Company Description: Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for …See details»
Contact Us - Omeros
The Omeros Building 201 Elliott Avenue West Seattle, WA 98119. 201 Elliott Avenue West Seattle, WA 98119. Information Request. Name (Required) Organization. Email (Required) …See details»
Omeros CEO and Key Executive Team | Craft.co
Omeros's Chairman, Chief Executive Officer & Director is Gregory A. Demopulos. Other executives include Timothy M Duffy, Vice President, Business Development; Peter B. Cancelmo, Vice President, General Counsel and Secretary and 15 …See details»
Omeros Corporation Reports Fourth Quarter and Year-End 2024 …
6 hours ago SEATTLE, March 31, 2025--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the fourth …See details»
Omeros Company Profile - Office Locations, Competitors, Revenue …
Oct 29, 2024 Omeros has 5 employees at their 1 location and $73.81 m in annual revenue in FY 2020. See insights on Omeros including office locations, competitors, revenue, financials, …See details»
Omeros Patient Resources: Clinical Trials, Partnerships, & Advocacy
Apr 8, 2019 In everything that we do at Omeros, our primary focus is the patient. Rather than developing “me-too” products, we are tackling serious diseases and disorders to improve or …See details»
Omeros - Overview, News & Similar companies | ZoomInfo.com
May 15, 2024 Omeros is a Seattle-based biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeuti cs for large-market as …See details»
Omeros Corporation (LON: 0KBU) Company Profile & Overview
Jan 23, 2025 Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan …See details»
Omeros Corporation - Omeros Corporation Reports Fourth …
Dec 31, 2024 – Conference Call Today at 4:30 p.m. ET –. SEATTLE--(BUSINESS WIRE)--Mar. 31, 2025-- Omeros Corporation (Nasdaq: OMER) today announced recent highlights and …See details»
Omeros Corporation Reports Fourth Quarter and Year-End 2024
3 hours ago OMEROS CORPORATION. UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (In thousands, except share and per share data) Three Months Ended. Year Ended. December 31, December 31, 2024. 2023. 2024. 2023. Costs and expenses: Research and development $ 23,320 $ 28,890 $ 119,523 $ 114,870 . Selling, …See details»
Omeros 2025 Company Profile: Stock Performance & Earnings
Omeros General Information Description. Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small …See details»
Omeros Investor Relations - Reports, Filings, OMER Stock Quote
4 days ago SEATTLE --(BUSINESS WIRE)--Mar. 26, 2025-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter and …See details»
Working At Omeros: Company Overview and Culture - Zippia
Mar 14, 2024 The average an Omeros salary in the United States is $84,137 per year. Omeros employees in the top 10 percent can make over $133,000 per year, while Omeros employees …See details»
Omeros Corporation (OMER) reports earnings - Quartz
1 day ago Omeros is also advancing its OMS1029 program, a long-acting antibody targeting MASP-2, and zaltenibart (OMS906), which targets MASP-3 for conditions such as paroxysmal …See details»